Morgan Stanley raised the price target for the Nautilus Biotechnology Inc. (NASDAQ:NAUT) stock to “an Equal-weight”. The rating was released on January 06, 2022, according to finviz. The research report from Goldman has initiated the stock to Neutral, with a price target set at $10. The stock was initiated by Jefferies, who disclosed in a research note on July 13, 2021, to Buy and set the price objective to $13.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Nautilus Biotechnology Inc. (NASDAQ:NAUT) raised 0.44% to close Friday’s market session at $2.26, higher as compared to yesterday’s close. The stock price fluctuated between $2.21 and $2.34 throughout the trading session with the volume trading being 792052 shares, which represented a significant variation when compared to the three months average volume of 128.96K shares. The firm’s stock price fluctuated 1.80% within the last five trades and 9.71% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 2.26% in the last 6 months and 39.51% was added to its value over the previous 3 months. NAUT stock is trading at a margin of 6.60%, 12.38% and -0.26% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
As of the close of trading, NAUT deals in the Healthcare domain. The stock is trading -55.38 percent below its 52-week high and 50.67 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -37.44. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Nautilus Biotechnology Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $279.65 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 0.90, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 8.20 percent of Nautilus Biotechnology Inc. shares are owned by insiders, and 45.50 percent are held by financial institutions. Sankar Subramanian, the Senior VP, Product Development at Nautilus Biotechnology Inc. (NAUT) has bought 5,000 shares of firm on Sep 27 at a price of $2.03 against the total amount of $10149.0. In another inside trade, Sankar Subramanian, Senior VP, Product Development of Nautilus Biotechnology Inc. (NASDAQ:NAUT) bought 10,000 shares of the firm on Sep 26 for a total worth of $20250.0 at a price of $2.02. An inside trade which took place on Sep 23, Chief People Officer of Nautilus Biotechnology Inc. Weld Gwen E bought 30,000 shares of firm against total price of $60765.0 at the cost of $2.03 per share.